ECSP034639A - Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos - Google Patents

Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos

Info

Publication number
ECSP034639A
ECSP034639A EC2003004639A ECSP034639A ECSP034639A EC SP034639 A ECSP034639 A EC SP034639A EC 2003004639 A EC2003004639 A EC 2003004639A EC SP034639 A ECSP034639 A EC SP034639A EC SP034639 A ECSP034639 A EC SP034639A
Authority
EC
Ecuador
Prior art keywords
pharmacologically active
pharmaceutical compositions
active agent
agent
oral supply
Prior art date
Application number
EC2003004639A
Other languages
English (en)
Inventor
Joseph M Ault
Moise Azria
Simon David Bateman
Joseph Sikora
Gregory Sparta
Rebecca Fai-Ying Yang
Jie Xiao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP034639A publication Critical patent/ECSP034639A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se dan a conocer composiciones farmacéuticas sólidas adecuadas para el suministro oral de agentes farmacológica mente activos, por ejemplo péptidos, las cuales comprenden una cantidad terapéuticamente efectiva de un agente farmacológica mente activo, una crospovidona o providona, y un agente de suministro para este agente farmacológica mente activo,. Las composiciones proporcionan una excelente biodisponiblidad oral de los agentes farmacológica mente activos, en particular calcitonina
EC2003004639A 2000-12-06 2003-06-04 Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos ECSP034639A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25172900P 2000-12-06 2000-12-06

Publications (1)

Publication Number Publication Date
ECSP034639A true ECSP034639A (es) 2003-07-25

Family

ID=22953160

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004639A ECSP034639A (es) 2000-12-06 2003-06-04 Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos

Country Status (26)

Country Link
US (1) US7049283B2 (es)
EP (1) EP1341526B1 (es)
JP (2) JP4898078B2 (es)
KR (1) KR100847695B1 (es)
CN (1) CN1304048C (es)
AT (1) ATE513541T1 (es)
AU (2) AU2002234547B2 (es)
BR (2) BRPI0115965B1 (es)
CA (1) CA2436599C (es)
CY (1) CY1112562T1 (es)
CZ (1) CZ305418B6 (es)
DK (1) DK1341526T3 (es)
EC (1) ECSP034639A (es)
ES (1) ES2367009T3 (es)
HU (1) HU230632B1 (es)
IL (2) IL155992A0 (es)
MX (1) MXPA03005096A (es)
NO (1) NO332936B1 (es)
NZ (1) NZ526196A (es)
PL (1) PL209703B1 (es)
PT (1) PT1341526E (es)
RU (1) RU2287999C2 (es)
SI (1) SI1341526T1 (es)
SK (1) SK287613B6 (es)
WO (1) WO2002045754A2 (es)
ZA (1) ZA200304295B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
JP5073153B2 (ja) * 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
TWI307279B (en) * 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20070065505A1 (en) * 2003-07-11 2007-03-22 Shoufeng Li Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
ES2398237T3 (es) * 2003-07-23 2013-03-14 Novartis Ag Uso de calcitonina en osteoartritis
PT3395338T (pt) * 2003-09-12 2019-07-23 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
CN1968704B (zh) * 2004-05-19 2010-12-08 爱密斯菲尔科技公司 局部用色甘酸制剂
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
CN105641686A (zh) 2005-09-19 2016-06-08 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
EP1991241A4 (en) * 2006-02-23 2009-07-08 Iomedix Sleep Internat Srl COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
BRPI0716261A2 (pt) * 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
CA2572004A1 (en) * 2006-12-08 2008-06-08 Bernard Charles Sherman Tablets comprising entacapone and crospovidone
CN101621991A (zh) * 2007-03-02 2010-01-06 诺瓦提斯公司 降钙素的口服施用
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
JP5740689B2 (ja) * 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
CA2755068C (en) * 2009-03-12 2018-11-06 Keybioscience Ag Treatment of diabetes and metabolic syndrome
EP2579868B1 (en) 2010-06-09 2018-03-07 Emisphere Technologies, Inc. Oral iron deficiency therapy
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
NZ735250A (en) * 2015-07-08 2020-08-28 Research & Business Found Sungkyunkwan Univ Pyrrolidine carboxamido derivatives and methods for preparing and using the same
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
CN107080739A (zh) * 2017-04-17 2017-08-22 深圳市泛谷药业股份有限公司 一种用于口服给药的固体快速释放布南色林片及其制备方法
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) * 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015633A (en) 1987-04-27 1991-05-14 E. R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en) 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
IT1238072B (it) 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) * 1991-06-25 1993-01-08 Pioneer Electron Corp 光記録媒体
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
EP1057479A1 (en) 1994-12-14 2000-12-06 Enbalt Trading Limited Pharmaceutical tablet formulations for direct compression
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE383169T1 (de) 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
OA11529A (en) 1998-03-16 2004-05-07 Inhale Therapeutic Syst Aerosolized active agent delivery.
WO2000057857A1 (en) 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
WO2000059480A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making

Also Published As

Publication number Publication date
AU2002234547B2 (en) 2005-03-24
CA2436599A1 (en) 2002-06-13
PT1341526E (pt) 2011-09-01
HUP0302319A3 (en) 2013-04-29
KR100847695B1 (ko) 2008-07-23
JP2009185052A (ja) 2009-08-20
JP4898078B2 (ja) 2012-03-14
MXPA03005096A (es) 2003-09-05
SK6882003A3 (en) 2004-01-08
HU230632B1 (hu) 2017-05-29
IL155992A0 (en) 2003-12-23
DK1341526T3 (da) 2011-10-03
PL209703B1 (pl) 2011-10-31
PL362247A1 (en) 2004-10-18
NO20032511L (no) 2003-06-03
NO332936B1 (no) 2013-02-04
BRPI0115965B1 (pt) 2017-09-26
BR0115965A (pt) 2003-10-28
KR20040018309A (ko) 2004-03-03
NO20032511D0 (no) 2003-06-03
HUP0302319A2 (hu) 2003-11-28
JP2004515480A (ja) 2004-05-27
AU3454702A (en) 2002-06-18
ZA200304295B (en) 2004-05-10
SK287613B6 (sk) 2011-04-05
CZ20031566A3 (cs) 2003-09-17
WO2002045754A2 (en) 2002-06-13
CY1112562T1 (el) 2016-02-10
ES2367009T3 (es) 2011-10-27
HK1059565A1 (en) 2004-07-09
US7049283B2 (en) 2006-05-23
IL155992A (en) 2008-04-13
RU2287999C2 (ru) 2006-11-27
US20020123459A1 (en) 2002-09-05
SI1341526T1 (sl) 2011-10-28
WO2002045754A3 (en) 2003-01-03
EP1341526A2 (en) 2003-09-10
NZ526196A (en) 2005-01-28
ATE513541T1 (de) 2011-07-15
CN1304048C (zh) 2007-03-14
CA2436599C (en) 2011-01-25
CZ305418B6 (cs) 2015-09-09
EP1341526B1 (en) 2011-06-22
CN1479612A (zh) 2004-03-03

Similar Documents

Publication Publication Date Title
ECSP034639A (es) Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos
ID27504A (id) Formulasi oral baru
ITMI20001173A0 (it) Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
DE602004023093D1 (de) N mit einem abgabemittel in mikronisierter form
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
BRPI0113331B8 (pt) derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
DE60335557D1 (de) Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
EP1392241A4 (en) SYSTEM FOR THE OSMOTIC RELEASE OF PHARMACEUTIC EFFECTIVENESS
AR044775A1 (es) Composiciones farmaceuticas de atorvastatina
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
PY0206703A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
IT1255460B (it) Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
BR0112847A (pt) Uso de uma forma de dosagem sólida
ECSP014082A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
ECSP003685A (es) Formulaciones orales de liberacion controlada
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
FR2798288B1 (fr) Compositions vaccinales destinees a une administration par voie muqueuse
NO20034873D0 (no) Bredspektret 2-(amino)-benzoxazolsulfonamid HIV proteasehemmere
GT199700112A (es) Nuevas microesferas farmaceuticas para administracion oral.
UY27122A1 (es) Una composición farmacéutica que comprende de 2 a 4 mg de 5-(a-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona
GT200100223A (es) Composiciones hidroliticamente inestables.